<?xml version="1.0" encoding="UTF-8"?>
<p>The European and American Cardiology Societies, remarked that there is no evidence of a noxious effect of RAS inhibitors in patients affected by COVID-19 (
 <xref rid="B128" ref-type="bibr">128</xref>, 
 <xref rid="B129" ref-type="bibr">129</xref>). Moreover, discontinuation of RAS inhibitor both in healthy and infected individuals could be dangerous, especially in high-risk patients, so they suggest to maintain the ongoing therapy (
 <xref rid="B130" ref-type="bibr">130</xref>).
</p>
